Sequestration Hurts Kids With Cancer
via The Cancer Letter,
an interview with Dr. Peter Adamson, Chair, Children's Oncology Group
Sequestration is forcing the Children’s Oncology Group to confront a profound ethical dilemma. Doctors who develop treatments for children’s cancer may have to choose between initiating new trials and continuing current studies, said Peter Adamson, chair of the Children’s Oncology Group and chief of the Division of Clinical Pharmacology and Therapeutics at the Children’s Hospital of Philadelphia.
“Do we delay or not pursue new studies, versus waiting to get the complete studies and get the answers from the ongoing studies?” Adamson said in a conversation with Paul Goldberg, editor and publisher of The Cancer Letter. “It sets us back, and it sets the outcomes for children with cancer back if we can’t move our highest-priority ideas forward into the clinical research and answer these important questions.” A recording of the conversation is available on The Cancer Letter website.
Paul Goldberg: Will sequestration affect pediatric trials in the same way that it will affect adult trials?
Peter Adamson: I think there is going to be some similarities, but there is also going to be some added challenges that we face in pediatric trials.
Continue Reading Here - The Cancer Letter or download the attached file.